<DOC>
	<DOCNO>NCT00004346</DOCNO>
	<brief_summary>OBJECTIVES : I. Assess biosynthesis cholesterol cholestanol , measure turnover individual sterol bile acid patient cerebrotendinous xanthomatosis cholesterol- cholestanol-free diet . II . Assess biosynthesis cholesterol cholestanol , measure turnover individual sterol bile acid patient lovastatin chenodeoxycholic acid .</brief_summary>
	<brief_title>Phase II Study Cholesterol- Cholestanol-Free Diet , Lovastatin , Chenodeoxycholic Acid Cerebrotendinous Xanthomatosis</brief_title>
	<detailed_description>PROTOCOL OUTLINE : Following 2-week baseline assessment , patient participate feed study 3 week . The diet free cholesterol cholestanol . For next 4 week , patient return typical diet medicate daily lovastatin chenodeoxycholic acid . The feeding study repeat additional 3 week , patient take either lovastatin chenodeoxycholic acid .</detailed_description>
	<mesh_term>Xanthomatosis</mesh_term>
	<mesh_term>Xanthomatosis , Cerebrotendinous</mesh_term>
	<mesh_term>Chenodeoxycholic Acid</mesh_term>
	<mesh_term>Lovastatin</mesh_term>
	<mesh_term>L 647318</mesh_term>
	<mesh_term>Dihydromevinolin</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Cerebrotendinous xanthomatosis</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2003</verification_date>
	<keyword>cerebrotendinous xanthomatosis</keyword>
	<keyword>inborn error metabolism</keyword>
	<keyword>rare disease</keyword>
</DOC>